AAAAAA

   
Results: 1-25 | 26-36
Results: 1-25/36
MYELOSUPPRESSIVE CHANGES FROM SINGLE OR REPEATED DOSES OF RADIOANTIBODY THERAPY - EFFECT OF BONE-MARROW TRANSPLANTATION, CYTOKINES, AND HEMATOPOIETIC SUPPRESSION
Authors: BLUMENTHAL RD ALISAUSKAS R LEW W SHARKEY RM GOLDENBERG DM
Citation: Rd. Blumenthal et al., MYELOSUPPRESSIVE CHANGES FROM SINGLE OR REPEATED DOSES OF RADIOANTIBODY THERAPY - EFFECT OF BONE-MARROW TRANSPLANTATION, CYTOKINES, AND HEMATOPOIETIC SUPPRESSION, Experimental hematology, 26(9), 1998, pp. 859-868
ANTIBODY FRAGMENTS IN RADIOIMMUNOTHERAPY (RIT) - THE ROLE OF THE RADIATION-DOSE AND DOSE-RATE ON TOXICITY AND ANTITUMOR EFFICACY
Authors: BEHR TM MEMTSOUDIS S SHARKEY RM BLUMENTHAL RD DUNN RM GOLDENBERG DM BECKER W
Citation: Tm. Behr et al., ANTIBODY FRAGMENTS IN RADIOIMMUNOTHERAPY (RIT) - THE ROLE OF THE RADIATION-DOSE AND DOSE-RATE ON TOXICITY AND ANTITUMOR EFFICACY, The Journal of nuclear medicine, 39(5), 1998, pp. 439-439
PRECLINICAL MULTIMODAL THERAPY OF 3 HUMAN COLONIC-CANCER XENOGRAFTS USING RADIOIMMUNOTHERAPY (RAIT) AND CHEMOTHERAPY
Authors: BLUMENTHAL RD LEW W REISING A MODRAK D OSORIO L GOLD DV YING X GOLDENBERG DM
Citation: Rd. Blumenthal et al., PRECLINICAL MULTIMODAL THERAPY OF 3 HUMAN COLONIC-CANCER XENOGRAFTS USING RADIOIMMUNOTHERAPY (RAIT) AND CHEMOTHERAPY, The Journal of nuclear medicine, 39(5), 1998, pp. 1088-1088
EXPERIMENTAL STUDIES ON THE ROLE OF ANTIBODY FRAGMENTS IN CANCER RADIO-IMMUNOTHERAPY - INFLUENCE OF RADIATION-DOSE AND DOSE-RATE ON TOXICITY AND ANTITUMOR EFFICACY
Authors: BEHR TM MEMTSOUDIS S SHARKEY RM BLUMENTHAL RD DUNN RM GRATZ S WIELAND E NEBENDAHL K SCHMIDBERGER H GOLDENBERG DM BECKER W
Citation: Tm. Behr et al., EXPERIMENTAL STUDIES ON THE ROLE OF ANTIBODY FRAGMENTS IN CANCER RADIO-IMMUNOTHERAPY - INFLUENCE OF RADIATION-DOSE AND DOSE-RATE ON TOXICITY AND ANTITUMOR EFFICACY, International journal of cancer, 77(5), 1998, pp. 787-795
THERAPEUTIC EFFICACY AND DOSE-LIMITING TOXICITY OF AUGER-ELECTRON VS.BETA-EMITTER IN RADIOIMMUNOTHERAPY WITH INTERNALIZING ANTIBODIES - EVALUATION OF I-125-LABELED VS I-131-LABELED CO17-1A IN A HUMAN COLORECTAL-CANCER MODEL
Authors: BEHR TM SGOUROS G VOUGIOUKAS V MEMTSOUDIS S GRATZ S SCHMIDBERGER H BLUMENTHAL RD GOLDENBERG DM BECKER W
Citation: Tm. Behr et al., THERAPEUTIC EFFICACY AND DOSE-LIMITING TOXICITY OF AUGER-ELECTRON VS.BETA-EMITTER IN RADIOIMMUNOTHERAPY WITH INTERNALIZING ANTIBODIES - EVALUATION OF I-125-LABELED VS I-131-LABELED CO17-1A IN A HUMAN COLORECTAL-CANCER MODEL, International journal of cancer, 76(5), 1998, pp. 738-748
DEVELOPMENT OF A STREPTAVIDIN-ANTI-CARCINOEMBRYONIC ANTIGEN-ANTIBODY,RADIOLABELED BIOTIN PRETARGETING METHOD FOR RADIOIMMUNOTHERAPY OF COLORECTAL-CANCER - STUDIES IN A HUMAN COLON-CANCER XENOGRAFT MODEL
Authors: SHARKEY RM KARACAY H GRIFFITHS GL BEHR TM BLUMENTHAL RD MATTES MJ HANSEN HJ GOLDENBERG DM
Citation: Rm. Sharkey et al., DEVELOPMENT OF A STREPTAVIDIN-ANTI-CARCINOEMBRYONIC ANTIGEN-ANTIBODY,RADIOLABELED BIOTIN PRETARGETING METHOD FOR RADIOIMMUNOTHERAPY OF COLORECTAL-CANCER - STUDIES IN A HUMAN COLON-CANCER XENOGRAFT MODEL, Bioconjugate chemistry, 8(4), 1997, pp. 595-604
CHANGES IN TUMOR VASCULAR-PERMEABILITY IN RESPONSE TO EXPERIMENTAL RADIOIMMUNOTHERAPY - A COMPARATIVE-STUDY OF 11 XENOGRAFTS
Authors: BLUMENTHAL RD SHARKEY RM KASHI R SIDES K STEIN R GOLDENBERG DM
Citation: Rd. Blumenthal et al., CHANGES IN TUMOR VASCULAR-PERMEABILITY IN RESPONSE TO EXPERIMENTAL RADIOIMMUNOTHERAPY - A COMPARATIVE-STUDY OF 11 XENOGRAFTS, Tumor biology, 18(6), 1997, pp. 367-377
ADVANTAGE OF RESIDUALIZING RADIOLABELS FOR AN INTERNALIZING ANTIBODY AGAINST THE B-CELL LYMPHOMA ANTIGEN, CD22
Authors: SHARKEY RM BEHR TM MATTES MJ STEIN R GRIFFITHS GL SHIH LB HANSEN HJ BLUMENTHAL RD DUNN RM JUWEID ME GOLDENBERG DM
Citation: Rm. Sharkey et al., ADVANTAGE OF RESIDUALIZING RADIOLABELS FOR AN INTERNALIZING ANTIBODY AGAINST THE B-CELL LYMPHOMA ANTIGEN, CD22, Cancer immunology and immunotherapy, 44(3), 1997, pp. 179-188
RADIOIMMUNOTHERAPY OF COLORECTAL-CANCER IN MINIMAL RESIDUAL DISEASE AND IN AN ADJUVANT SETTING - EVALUATION OF I-131-LABELED AND Y-90-LABELED IGG AND FRAGMENTS VERSUS STANDARD CHEMOTHERAPY IN A NUDE-MOUSE MODEL
Authors: BEHR TM MEMTSOUDIS S BLUMENTHAL RD DUNN RM NEBENDAHL K SHARKEY RM GOLDENBERG DM BECKER W
Citation: Tm. Behr et al., RADIOIMMUNOTHERAPY OF COLORECTAL-CANCER IN MINIMAL RESIDUAL DISEASE AND IN AN ADJUVANT SETTING - EVALUATION OF I-131-LABELED AND Y-90-LABELED IGG AND FRAGMENTS VERSUS STANDARD CHEMOTHERAPY IN A NUDE-MOUSE MODEL, The Journal of nuclear medicine, 38(5), 1997, pp. 14-14
COMPLETE VERSUS FRAGMENTED, I-131-LABELED AND Y-90-LABELED ANTIBODIESFOR RADIOIMMUNOTHERAPY (RAIT) OF CEA-EXPRESSING CANCERS - INFLUENCE OF DOSE-RATE AND RENAL ACCRETION ON TOXICITY AND ANTI-TUMOR-EFFICACY
Authors: BEHR TM MEMTSOUDIS S BLUMENTHAL RD DUNN RM SHARKEY RM GOLDENBERG DM BECKER W
Citation: Tm. Behr et al., COMPLETE VERSUS FRAGMENTED, I-131-LABELED AND Y-90-LABELED ANTIBODIESFOR RADIOIMMUNOTHERAPY (RAIT) OF CEA-EXPRESSING CANCERS - INFLUENCE OF DOSE-RATE AND RENAL ACCRETION ON TOXICITY AND ANTI-TUMOR-EFFICACY, The Journal of nuclear medicine, 38(5), 1997, pp. 107-107
PREDICTION OF MYELOTOXICITY AFTER RADIOIMMUNOTHERAPY WITH I-131-LABELED ANTICARCINOEMBRYONIC ANTIGEN MONOCLONAL-ANTIBODIES IN PATIENTS WITHCOLORECTAL CANCERS
Authors: JUWEID M ZHANG CH BLUMENTHAL RD SHARKEY RM DUNLOP D DUNN R GOLDENBERG DM
Citation: M. Juweid et al., PREDICTION OF MYELOTOXICITY AFTER RADIOIMMUNOTHERAPY WITH I-131-LABELED ANTICARCINOEMBRYONIC ANTIGEN MONOCLONAL-ANTIBODIES IN PATIENTS WITHCOLORECTAL CANCERS, The Journal of nuclear medicine, 38(5), 1997, pp. 970-970
SELECTION OF RADIOIMMUNOCONJUGATES FOR THE THERAPY OF WELL-ESTABLISHED OR MICROMETASTATIC COLON-CARCINOMA
Authors: SHARKEY RM BLUMENTHAL RD BEHR TM WONG GY HAYWOOD L FORMAN D GRIFFITHS GL GOLDENBERG DM
Citation: Rm. Sharkey et al., SELECTION OF RADIOIMMUNOCONJUGATES FOR THE THERAPY OF WELL-ESTABLISHED OR MICROMETASTATIC COLON-CARCINOMA, International journal of cancer, 72(3), 1997, pp. 477-485
APPLICATION OF CYTOKINE INTERVENTION FOR IMPROVED RADIO-ANTIBODY DOSEDELIVERY
Authors: BLUMENTHAL RD SHARKEY RM HAYWOOD L BEHR T GOLDENBERG DM
Citation: Rd. Blumenthal et al., APPLICATION OF CYTOKINE INTERVENTION FOR IMPROVED RADIO-ANTIBODY DOSEDELIVERY, International journal of cancer, 72(1), 1997, pp. 166-173
REDUCTION IN THE DURATION OF MYELOTOXICITY ASSOCIATED WITH RADIOIMMUNOTHERAPY WITH INFUSIONS OF THE HEMOREGULATORY PEPTIDE, HP5B IN MICE
Authors: ALISAUSKAS RM GOLDENBERG DM SHARKEY RM BLUMENTHAL RD
Citation: Rm. Alisauskas et al., REDUCTION IN THE DURATION OF MYELOTOXICITY ASSOCIATED WITH RADIOIMMUNOTHERAPY WITH INFUSIONS OF THE HEMOREGULATORY PEPTIDE, HP5B IN MICE, International journal of cancer, 70(3), 1997, pp. 323-329
IMPROVED TREATMENT OF MEDULLARY-THYROID CANCER IN A NUDE-MOUSE MODEL BY COMBINED RADIOIMMUNOCHEMOTHERAPY - DOXORUBICIN POTENTIATES THE THERAPEUTIC EFFICACY OF RADIOLABELED ANTIBODIES IN A RADIORESISTANT TUMOR TYPE
Authors: BEHR TM WULST E RADETZKY S BLUMENTHAL RD DUNN RM GRATZ S RAVEFRANK M SCHMIDBERGER H RAUE F BECKER W
Citation: Tm. Behr et al., IMPROVED TREATMENT OF MEDULLARY-THYROID CANCER IN A NUDE-MOUSE MODEL BY COMBINED RADIOIMMUNOCHEMOTHERAPY - DOXORUBICIN POTENTIATES THE THERAPEUTIC EFFICACY OF RADIOLABELED ANTIBODIES IN A RADIORESISTANT TUMOR TYPE, Cancer research, 57(23), 1997, pp. 5309-5319
OVERCOMING THE NEPHROTOXICITY OF RADIOMETAL-LABELED IMMUNOCONJUGATES - IMPROVED CANCER-THERAPY ADMINISTERED TO A NUDE-MOUSE MODEL IN RELATION TO THE INTERNAL RADIATION-DOSIMETRY
Authors: BEHR TM SHARKEY RM SGOUROS G BLUMENTHAL RD DUNN RM KOLBERT K GRIFFITHS GL SIEGEL JA BECKER WS GOLDENBERG DM
Citation: Tm. Behr et al., OVERCOMING THE NEPHROTOXICITY OF RADIOMETAL-LABELED IMMUNOCONJUGATES - IMPROVED CANCER-THERAPY ADMINISTERED TO A NUDE-MOUSE MODEL IN RELATION TO THE INTERNAL RADIATION-DOSIMETRY, Cancer, 80(12), 1997, pp. 2591-2610
DEFINING THE OPTIMAL SPACING BETWEEN REPEAT RADIOANTIBODY DOSES IN EXPERIMENTAL-MODELS - IS THERE AN ACCURATE MEASUREMENT FOR HEMATOPOIETICRECOVERY
Authors: BLUMENTHAL RD ALISAUSKAS R JUWEID M SHARKEY RM GOLDENBERG DM
Citation: Rd. Blumenthal et al., DEFINING THE OPTIMAL SPACING BETWEEN REPEAT RADIOANTIBODY DOSES IN EXPERIMENTAL-MODELS - IS THERE AN ACCURATE MEASUREMENT FOR HEMATOPOIETICRECOVERY, Cancer, 80(12), 1997, pp. 2624-2635
FACTORS INFLUENCING HEMATOLOGIC TOXICITY OF RADIOIMMUNOTHERAPY WITH I-131-LABELED ANTICARCINOEMBRYONIC ANTIGEN ANTIBODIES
Authors: JUWEID ME ZHANG CH BLUMENTHAL RD SHARKEY RM DUNN R DUNLOP D GOLDENBERG DM
Citation: Me. Juweid et al., FACTORS INFLUENCING HEMATOLOGIC TOXICITY OF RADIOIMMUNOTHERAPY WITH I-131-LABELED ANTICARCINOEMBRYONIC ANTIGEN ANTIBODIES, Cancer, 80(12), 1997, pp. 2749-2753
OVERCOMING NEPHROTOXICITY IN THERAPY WITH RADIOMETAL-CONJUGATED ANTIBODY FRAGMENTS AND PEPTIDES - IMPROVEMENT OF THEIR THERAPEUTIC EFFICACY
Authors: BEHR TM SHARKEY RM BLUMENTHAL RD SGOUROS G DUNN RM ALISAUSKUS R GRIFFITHS G GOLDENBERG DM
Citation: Tm. Behr et al., OVERCOMING NEPHROTOXICITY IN THERAPY WITH RADIOMETAL-CONJUGATED ANTIBODY FRAGMENTS AND PEPTIDES - IMPROVEMENT OF THEIR THERAPEUTIC EFFICACY, The Journal of nuclear medicine, 37(5), 1996, pp. 374-374
Y-90 DOSIMETRY IN NUDE-MICE REQUIRES ACCOUNTING FOR CROSS-ORGAN RADIATION - EVALUATION OF 3 DOSIMETRIC MODELS IN RELATION TO OBSERVED BIOLOGICAL EFFECTS
Authors: BEHR TM SGOUROS G SHARKEY RM DUNN RM BLUMENTHAL RD KOLBERT K SIEGEL JA GOLDENBERG DM
Citation: Tm. Behr et al., Y-90 DOSIMETRY IN NUDE-MICE REQUIRES ACCOUNTING FOR CROSS-ORGAN RADIATION - EVALUATION OF 3 DOSIMETRIC MODELS IN RELATION TO OBSERVED BIOLOGICAL EFFECTS, The Journal of nuclear medicine, 37(5), 1996, pp. 400-400
MYELOSUPPRESSION AND THERAPEUTIC POTENTIAL USING DOSE FRACTIONATION (FX) OF Y-90 MU-9 ANTI-CSAP INTACT IGG AND F(AB')(2) USING COLONIC-CANCER XENOGRAFT MODELS
Authors: BLUMENTHAL RD SHARKEY RM SIDES K GOLDENBERG DM
Citation: Rd. Blumenthal et al., MYELOSUPPRESSION AND THERAPEUTIC POTENTIAL USING DOSE FRACTIONATION (FX) OF Y-90 MU-9 ANTI-CSAP INTACT IGG AND F(AB')(2) USING COLONIC-CANCER XENOGRAFT MODELS, The Journal of nuclear medicine, 37(5), 1996, pp. 733-733
MULTIMODAL EXPERIMENTAL-THERAPY OF A SC COLONIC-CANCER XENOGRAFT USING RADIOIMMUNOTHERAPY (RAIT) AND CHEMOTHERAPY
Authors: BLUMENTHAL RD SHARKEY RM GOLD DV OSORIO L GOLDENBERG DM
Citation: Rd. Blumenthal et al., MULTIMODAL EXPERIMENTAL-THERAPY OF A SC COLONIC-CANCER XENOGRAFT USING RADIOIMMUNOTHERAPY (RAIT) AND CHEMOTHERAPY, The Journal of nuclear medicine, 37(5), 1996, pp. 737-737
ANTIBODY PENETRATION OF TUMOR GS-7 XENOGRAFTS IN NUDE-MICE - A MODEL FOR MUCINOUS ADENOCARCINOMA OF THE COLON
Authors: BLUMENTHAL RD STEIN R SHARKEY RM GOLDENBERG DM ONG GL KLEIN KM MATTES MJ
Citation: Rd. Blumenthal et al., ANTIBODY PENETRATION OF TUMOR GS-7 XENOGRAFTS IN NUDE-MICE - A MODEL FOR MUCINOUS ADENOCARCINOMA OF THE COLON, Cancer research, 56(15), 1996, pp. 3508-3515
IMPROVED EXPERIMENTAL CANCER-THERAPY BY RADIOANTIBODY DOSE INTENSIFICATION AS A RESULT OF SYNGENEIC BONE-MARROW TRANSPLANTATION
Authors: BLUMENTHAL RD SHARKEY RM FORMAN D WONG G HESS J GOLDENBERG DM
Citation: Rd. Blumenthal et al., IMPROVED EXPERIMENTAL CANCER-THERAPY BY RADIOANTIBODY DOSE INTENSIFICATION AS A RESULT OF SYNGENEIC BONE-MARROW TRANSPLANTATION, Experimental hematology, 23(10), 1995, pp. 1088-1097
QUANTITATIVE AND QUALITATIVE EFFECTS OF EXPERIMENTAL RADIOIMMUNOTHERAPY ON TUMOR VASCULAR-PERMEABILITY
Authors: BLUMENTHAL RD KASHI R SHARKEY RM GOLDENBERG DM
Citation: Rd. Blumenthal et al., QUANTITATIVE AND QUALITATIVE EFFECTS OF EXPERIMENTAL RADIOIMMUNOTHERAPY ON TUMOR VASCULAR-PERMEABILITY, International journal of cancer, 61(4), 1995, pp. 557-566
Risultati: 1-25 | 26-36